

# 28<sup>th</sup> Annual Scientific Congress

• **VIRTUAL**  
**3 – 5 July 2020**



Hong Kong College of Cardiology

## Allied Cardiovascular Health Professional Symposium

New Tools for Calcified Coronary Lesions Part II:  
Coronary Orbital Atherectomy System


Dr Chui, Shing Fung  
Associate Consultant  
Queen Elizabeth Hospital  
Hong Kong



# Our case

- 76/F
- Hx of DM, HT, hyperlipidemia
- Stable angina with positive Thallium perfusion scan over anterior wall
- Echo showed LVEF 50-55%, hypokinetic anterior and anteroseptal wall, mild to moderate MR, mild AR





# Coronary calcification

- Why is it important?






# Frequency of angio core lab moderate-severe calcification in 13 DES studies (despite being an exclusion criterion in most studies)

RAVEL	23.3% (27/116)
SIRIUS	17.1% (91/531)
E-SIRIUS	16.1% (28/174)
C-SIRIUS	12.0% (6/50)
TAXUS IV	18.3% (121/660)
TAXUS V	32.5% (185/570)
TAXUS VI	29.7% (65/219)
ENDEAVOR II	23.7% (140/590)
ENDEAVOR III	17.9% (78/436)
ENDEAVOR IV	33.2% (513/1546)
SPIRIT II	31.4% (91/290)
SPIRIT III	27.8% (277/997)
COMPARE	38.5% (693/1799)
<b>Pooled</b>	<b>29.0% (2,315/7,978)</b>




# Impact of heavy calcification

- Difficult stent delivery, risks of stent under-expansion
- May abrade polymers off DES
- Increase procedural complications
- Increase long-term event rates




# Approach for calcified lesion

Figure 2: Decision Algorithm for the Treatment of Calcified Coronary Lesions





IVUS = intravascular ultrasound; NC, non-compliant; OA = orbital atherectomy; OCT = optical coherence tomography; RA = rotational atherectomy.



JACC CV Intervention; 2014: 345-353

# How to definite severe calcification?

OCT-based calcium score	
1. Maximum calcium angle (°)	$\leq 180^\circ \Rightarrow$ 0 point $> 180^\circ \Rightarrow$ 2 points
2. Maximum calcium thickness (mm)	$\leq 0.5$ mm $\Rightarrow$ 0 point $> 0.5$ mm $\Rightarrow$ 1 point
3. Calcium length (mm)	$\leq 5.0$ mm $\Rightarrow$ 0 point $> 5.0$ mm $\Rightarrow$ 1 point
<b>Total score</b>	<b>0 to 4 points</b>






A Fujino, G Mintz, et al. EuroIntervention 2018;  
13:e2182-23189







# ADAPT-DES (11 center all-comers registry): Calcified lesion preparation

N = 2,644 patients





# Atherectomy: Two Approaches



## ROTATIONAL ATHERECTOMY


Uni-directional, front cutting, risk burr entrapment

Concentrically mounted burr rotates to create a lumen same size as the burr, larger vessels may require multiple burrs.

## ORBITAL ATHERECTOMY

Bi-directional differential sanding and pulsatile forces

- Eccentrically mounted crown creates centrifugal force:
- Designed to treat 360° of the vessel for improved compliance
  - Treat 2.5 mm to 4 mm vessel with a single crown



# Orbital Atherectomy System: Diamondback360

## Device Features

- Easy setup and use <2 mins
- Control of device in operating field
- Compatible with 6 Fr approach

## 0.012" Viper Wire Advance®

### ViperSlide® Lubricant

- ViperSlide reduces friction during operation
- 20ml ViperSlide per liter of saline



### OAS Pump

- Mounts directly on to an IV pole
- Provides power
- Delivers fluid
- Includes saline sensor

### Power on/off switch

- 8cm axial travel

### On-handle speed control

- Low (80K) and High Speed (120K)
- GlideAssist® (5K) for easier tracking & removal of OAD

### Electric motor powered handle

Ecc



# ViperSlide® Lubricant

- ViperSlide® reduces friction within the OAD
- 20 ml ViperSlide® per liter of saline



Ingredient	Amount
Soybean Oil	10%
Egg Yolk Phospholipids	1.2%
Glycerin	2.25%
Sodium Hydroxide (pH range is 6.0 to 8.9)	Quantity Sufficient
Water for Injection	Quantity Sufficient



# OAS Pump

Designed to allow continuous flow of blood and saline during orbit.  
Potentially minimizes thermal injury and decreases no-reflow  
and cardiac enzyme elevation


## Flow Rates (ml/min)\*

- OAD not spinning,  
prime button pressed: 30 - 36
- Not spinning: 17 - 19
- Spinning low: 20 - 34
- Spinning high: 17 - 29



# VIPERWIRE Advance<sup>®</sup> Coronary Guide Wire

- 325 cm long guide wire
- 25 mm long spring tip
- Spring tip stiffness: 1.4 grams force at 10 mm



Images are not to scale.




## DIAMONDBACK 360° CORONARY OAS CLASSIC CROWN FEATURES

Simple OAD setup

Electric powered handle with millisecond feedback








# Demonstration of Physics and Performance

High speed video (1200 fps) show Classic Crown in orbit at high speed (120k rpm)

$$F_c = \frac{mv^2}{R}$$

**Differential Orbital Sanding:**  
 The crown treats the entire lumen, different vessel diameters can be treated based on orbiting speed.  
 • Greater centrifugal force = Larger orbital diameter



3 mm

1.25 mm Classic Crown orbiting in a 3 mm glass tube at 120k rpm



Crown orbiting to tube diameter



## ORBITAL ATHERECTOMY

Advantage of eccentrically mounted, orbiting crown:

- Single **1.25mm crown (6F)** treats **2.5 to 4.0mm** vessels
- Orbiting crown **enables constant blood flow** and reduces heat
- **Bi-directional treatment** can reduce passes




OAS Orbit curve data represented is from testing using a carbon block model system with Classic Crown



1. Data on file.  
2. \*Based on minimum reference vessel diameter as determined by orbit testing in a carbon block model system

# GLIDE ASSIST FEATURE



No orbiting observed in glide mode



- Glide Assist feature: slow spinning at 5K RPM's to reduce guidewire friction




# ORBIT II

Prospective, multi-center trial in the United States

Single arm - As there were no FDA-approved percutaneous treatments specifically for patients with severely calcified coronary lesions.

**443 subjects enrolled at 49 U.S. Sites**



**Primary Safety Endpoint: MACE** (MI= CK-MB>3x ULN, TVR, Cardiac Death)

**Primary Efficacy Endpoint: Procedural Success**

- Success in facilitating stent delivery with a final residual stenosis of <50% (as determined by Angiographic Core Lab) and free from in-hospital MACE




# ORBIT II: Primary Safety Endpoint

Prospective, single arm, multi-center trial to evaluate the safety and efficacy of OAS to prepare de novo, severely calcified coronary lesions for enabling stent placement (N=443)

## 30 Day MACE Rate Components:

<b>MI (CK-MB &gt;3x ULN):</b>	<b>9.7%</b>
Non Q-wave	8.8%
Q-wave	0.9%
<b>TVR/TLR:</b>	<b>1.4%</b>
<b>Cardiac death:</b>	<b>0.2%</b>




# ORBIT II: Primary Efficacy Endpoint

Prospective, single arm, multi-center trial to evaluate the safety and efficacy of OAS to prepare de novo, severely calcified coronary lesions for enabling stent placement (N=443)


## Procedural Success Components:

<b>Successful Stent delivered:</b>	<b>97.7%</b>
<b>Less than 50% residual stenosis:</b>	<b>98.6%</b>
<b>In hospital MACE:</b>	<b>9.8%</b>
MI (CK-MB >3x ULN):	<b>9.3%</b>
Non Q-wave	8.6%
Q-wave	0.7%
TVR/TLR:	<b>0.7%</b>
Cardiac death:	<b>0.2%</b>



# COAST Study Design

- To evaluate the performance of the Coronary OAS Micro Crown in treating *de novo*, severely calcified coronary lesions
  - Prospective, single-arm, multi-center Investigational Device Exemption (IDE) study conducted in the US and Japan
  - Harmonization by Doing (regulatory collaboration between US and Japan)




- Same Primary Endpoints as ORBIT II



# COAST Primary Safety Endpoint

## 30-Day MACE Rate Components:

MI (CK-MB >3x ULN):	<b>14.0%</b>
Non Q-wave	12.0%
Q-wave	2.0%
TVR/TLR:	<b>1.0%</b>
TLR	1.0%
Cardiac death:	<b>1.0%</b>



1. Chambers JW, et al. JACC Cardiovasc Interv. 2014;7:510-8.





# COAST Primary Efficacy Endpoint

## Procedural Success

### Components:

Successful Stent delivered:

99.0%

Less than 50% residual stenosis:

99.0%

In-hospital MACE:


14.0%

TVR/TLR:

0%

Cardiac death:

1.0%



**ORBIT II** Procedural  
Success<sup>1</sup> = **88.9%**

(95% CI = 85.5%, 91.6%)

**COAST** Procedural


Success = **85.0%**

(95% CI = 76.5%, 91.4%)

Chambers JW, et al. JACC Cardiovasc Interv. 2014;7:510-8.



# ECLIPSE Trial Design






# Practical considerations



# Orbital Atherectomy is a Time Dependent Therapy


A breakdown of the physics that drive the system



\*Orbit chart data is from carbon block testing.

# No rush

- Slow transverse speed
  - Target at 1mm/sec



# Leverage Low Treatment Speed

$$F_c = \frac{mv^2}{R}$$


## Insights –

- Always begin treatment on low speed.
- Low speed is appropriate to treat most lesions. If additional treatment is required, consider use of high speed. High speed may be more suitable in larger and less tortuous anatomy.


## Rationale –

- Orbital atherectomy is a time dependent therapy; time and contact determine treatment effect.
- Because of the increased centrifugal force, high speed may be more suitable in larger and less tortuous anatomy.

- 1.25 mm Classic Crown orbiting in a 3 mm glass tube
- Crown orbiting to tube diameter




Treatment Diameter Is Affected By Traverse Speed And Rotation Speed<sup>2</sup>



# Technical Considerations: OAS in Aorto-Ostial Lesions


**Unrestricted Orbit**



Prashant Kaul (SCAI 2020)



# Technical Considerations: OAS in Aorto-Ostial Lesions






Prashant Kaul (SCAI 2020)






# Back to our case






OCT-based calcium score	
1. Maximum calcium angle (°)	$\leq 180^\circ$ = 0 point $> 180^\circ$ = 2 points
2. Maximum calcium thickness (mm)	$\leq 0.5$ mm = 0 point $> 0.5$ mm = 1 point
3. Calcium length (mm)	$\leq 5.0$ mm = 0 point $> 5.0$ mm = 1 point
<b>Total score</b>	<b>0 to 4 points</b>


OCT Score : 4






Orbital atherectomy performed





2.5x10mm and 3.5x10mm NC  
Balloon at 6atm





2.5x38mm and 3.5x18mm DES



# Conclusion

- Coronary calcification is very common among patients with ischemic heart disease, which can increase risks of procedural complications and later ischemic events
- Advanced imaging modalities are necessary for better visualization and quantify the degree of calcification
- For those heavily calcified lesion, use of orbital atherectomy can address calcification and vessel compliance for better stent expansion



Thank you

